GlassScriptPhysician profile
Sharisse Stephenson
NPI 1538358684
$23,334.13
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $12K · 2021: $4,694 · 2022: $4,711 · 2023: $1,269 · 2024: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $563 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $562.50 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12,283.56 | 2020-2021 | |
| Abbvie INC. | $6,634.30 | 2021-2024 | Qulipta, Ubrelvy |
| Biogen, INC. | $618.14 | 2020-2023 | Tysabri |
| Amgen INC. | $352.62 | 2021-2024 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $325.02 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $322.48 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $292.90 | 2022 | |
| Amneal Pharmaceuticals LLC | $286.98 | 2020-2023 | Rytary |
| Pfizer INC. | $270.15 | 2021-2024 | |
| Lilly USA, LLC | $226.66 | 2021-2023 | Emgality |
| Mdd US Operations, LLC | $224.27 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $175.26 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $154.93 | 2020-2021 | |
| Lundbeck LLC | $118.98 | 2021-2023 | Vyepti |
| Sk Life Science, INC. | $105.92 | 2021-2023 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharisse Stephenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.